FUM vs. PRTC, HZD, VRP, FARN, ARIX, AVCT, BVXP, 4BB, HVO, and CIR
Should you be buying Futura Medical stock or one of its competitors? The main competitors of Futura Medical include PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Faron Pharmaceuticals Oy (FARN), Arix Bioscience (ARIX), Avacta Group (AVCT), Bioventix (BVXP), 4basebio (4BB), hVIVO (HVO), and Circassia Group (CIR). These companies are all part of the "biotechnology" industry.
Futura Medical vs.
PureTech Health (LON:PRTC) and Futura Medical (LON:FUM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, community ranking, institutional ownership and dividends.
Futura Medical has higher revenue and earnings than PureTech Health. Futura Medical is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.
PureTech Health presently has a consensus target price of GBX 455, suggesting a potential upside of 203.74%. Given PureTech Health's stronger consensus rating and higher possible upside, equities research analysts clearly believe PureTech Health is more favorable than Futura Medical.
PureTech Health has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Futura Medical has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.
PureTech Health received 344 more outperform votes than Futura Medical when rated by MarketBeat users. Likewise, 86.60% of users gave PureTech Health an outperform vote while only 64.36% of users gave Futura Medical an outperform vote.
79.9% of PureTech Health shares are owned by institutional investors. Comparatively, 35.7% of Futura Medical shares are owned by institutional investors. 15.9% of PureTech Health shares are owned by insiders. Comparatively, 32.1% of Futura Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
PureTech Health has a net margin of 0.00% compared to Futura Medical's net margin of -44.68%. PureTech Health's return on equity of -22.07% beat Futura Medical's return on equity.
In the previous week, Futura Medical had 1 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Futura Medical and 1 mentions for PureTech Health. Futura Medical's average media sentiment score of 0.34 beat PureTech Health's score of 0.00 indicating that Futura Medical is being referred to more favorably in the news media.
Summary
PureTech Health beats Futura Medical on 11 of the 18 factors compared between the two stocks.
Get Futura Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for FUM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Futura Medical Competitors List
Related Companies and Tools
This page (LON:FUM) was last updated on 2/1/2025 by MarketBeat.com Staff
